PRQR ProQR Therapeutics NV

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

For the month of April 2022

 

Commission File Number: 001-36622

 

PROQR THERAPEUTICS N.V.

 

Zernikedreef 9

2333 CK Leiden

The Netherlands

Tel: +31 88 166 7000

(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x  Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

On April 13, 2022, ProQR Therapeutics N.V. (the “Company”) issued a press release titled, “ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy.” A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form F-3 (File No. 333-260775, File No. 333-260780 and File No. 333-248740).

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	PROQR THERAPEUTICS N.V.
Date: April 13, 2022	By:	/s/ Smital Shah
		Smital Shah
		Chief Financial Officer

 

 

 

 

INDEX TO EXHIBITS

 

Number		Description
99.1		Press Release of ProQR Therapeutics N.V. dated April 13, 2022.